Portfolio manager comments — Q4 2025
The fund rose by 2.5% in SEK during the final quarter of the year, while the benchmark index* increased by 4.1%. The primary reason for the relative underperformance was the profit warnings issued by Truecaller and Surgical Science, whose shares fell by approximately 53% and 63%, respectively, during the period. Excluding these two events, the fund’s return would have exceeded the index.
The fund’s largest positive contributor was Acast, which rose by approximately 63% following a strong quarterly report showing improved and increasing profitability.
Regarding portfolio changes, we began building a position in Volvo Cars ahead of the company’s third‑quarter report. Following the strong report, the holding was increased further. In addition, the fund invested in a number of smaller companies, each representing a limited share of the portfolio but together offering interesting potential. Examples include Alligo, Karnell, Ovzon, and Swedencare.
In the coming period, reporting of full‑year results will begin, which will be an important input for portfolio construction ahead of 2026. There are strong indications that the Swedish economy is entering a cyclical recovery, with improving conditions for consumers. This is expected to particularly benefit smaller companies, which generally have greater exposure to the domestic market than larger companies.
* SIX SRI Sweden 200 Small Cap Gross Index